CurrentUnitedHealthcarePolicy LABORATORY 033.5

Molecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions

Defines UnitedHealthcare coverage rationale for molecular/genomic testing in hematologic cancers including multi-gene NGS panels (≤50 genes), Comprehensive Genomic Profiling (CGP) for relapsed/recurrent AML, clonality and MRD testing with clonoSEQ, and lists tests and CPT/HCPCS codes referenced. Also states that other molecular tests/panels are unproven and not medically necessary.

Policy Summary

PayerUnitedHealthcare

PolicyMolecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions

Policy CodePolicy LABORATORY 033.5

Change TypeCPT/HCPCS codes added (0560U, 0561U)

Effective Date2025

Next Review Date

Key ActionTest must be ordered by a hematologist or oncologist and documentation may be required to assess whether the member meets the clinical criteria for coverage.

SourceLink

POLICY UPDATE CHANGES

Applicable CPT codes updated to reflect quarterly edits; added 0560U and 0561U

4Covered Indications explicitly listed

multipleCPT/HCPCS/Proprietary codes referenced

2Supported test categories

manyUnproven/not medically necessary tests

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Policy LABORATORY 033.5 (effective 2025) defines UnitedHealthcare coverage rationale for molecular and genomic testing in hematologic cancers. It states that multigene NGS panels (≤50 genes) are proven and medically necessary when ordered by a hematologist/oncologist for specified diagnoses (acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, and suspected myelodysplastic syndrome or myeloproliferative neoplasm).

The policy also supports Comprehensive Genomic Profiling (CGP) as proven and medically necessary for individuals with relapsed or recurrent acute myeloid leukemia (examples: FoundationOne Heme; Neo Comprehensive Heme Cancers).

Clonality assessment with clonoSEQ Clonality ID at initial diagnosis and clonoSEQ MRD for MRD assessment are stated as proven and medically necessary for multiple myeloma and acute lymphoblastic leukemia when ordered by a hematologist/oncologist.

The policy lists numerous molecular tests and approaches (including many specified products and techniques) as unproven and not medically necessary when used outside the stated indications, and references multiple CPT/HCPCS and proprietary codes for applicable testing.

Surface thresholds and monitoring highlights

Assay sensitivity range referencedGuidelines and policy cite MRD assay sensitivities ranging from 10^-4 to 10^-6 (NGS can reach 10^-6); validated MRD assays of 10^-4 or better recommended

Highest analytic sensitivity notedNGS/high-throughput sequencing and clonoSEQ described with detection down to 10^-6

Minimum recommended sensitivity for clinical MRD useUse validated MRD assessment technology with sensitivity of 10^-4 or better (NCCN/ policy requirement)

ASCO/CCO monitoring frequency (multiple myeloma maintenance)Assess depth of response each cycle; when less frequent, at minimum every 3 months on maintenance

ALL MRD timing guidanceNCCN recommends MRD assessment at end of induction, end of consolidation, and additional regimen-determined time points; baseline may be required for some techniques

Policy coding/administrative noteCPT updates added effective 07/01/2025 (0560U/0561U) for MRD-related services

Medically Necessary Coverage Criteria

Not Medically Necessary / Unproven

Applicable CPT/HCPCS and Proprietary Codes

Applicable CPT/HCPCS and Proprietary Codes referencedmixed

0017M	Oncology (diffuse large B-cell Lymphoma [DLBCL]); mRNA, gene expression profiling by fluorescent probe hybridization of 20 genes, formalin-fixed paraffin-embedded tissue, algorithm reported as cell of origin.
0120U	Oncology (B-cell Lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes.
0171U	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence.
0298U	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens...
0299U	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens...
0300U	Oncology (pan tumor), whole genome sequencing and optical genome mapping...
0331U	Oncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow...
0364U	Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of MRD with quantitation when appropriate.
0413U	Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements...
0485U	Oncology (solid tumor), cell-free DNA and RNA by next-generation sequencing; interpretative report...

1–10 of 19

1/2

Policy history code updatesmixed

0560U	newly added code (unspecified assay)
0561U	newly added code (unspecified assay)

Provider Actions and Billing Rules

Prior Authorization

Ordering provider requirement

Test must be ordered by a hematologist or oncologist; documentation may be required to assess whether member meets clinical criteria for coverage.

Documentation Required

Medical records documentation

Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage. Benefit coverage is determined by the member-specific benefit plan document and applicable laws; documentation of clinical records does not guarantee coverage.

Documentation Required

Select validated MRD assay and report sensitivity

Use a validated MRD assessment technology with sensitivity of 10^-4 or better (per NCCN); document specimen type (blood vs bone marrow) and the assay sensitivity. Note that for some techniques a baseline MRD assessment may be required.

Background and Evidence Summary

The policy background summarizes molecular profiling technologies used in hematologic malignancies, including Next Generation Sequencing (NGS) panels ranging from single-gene tests to whole exome/genome and targeted myeloid panels, comprehensive genomic profiling (CGP) that detects all classes of genomic alterations from one sample, and highly sensitive MRD assays (NGS-based MRD such as clonoSEQ) used to detect very low levels of residual disease.

Evidence reviewed highlights clinical utility: myeloid NGS panels improved diagnostic and prognostic yield (Soderquist et al. 2024 demonstrated high diagnostic/clincal impact), CGP is supported for relapsed/recurrent AML to identify actionable mutations, and MRD assays (including clonoSEQ and other NGS MRD methods) provide prognostic information across diseases (ALL, CLL, MM, AML) with sensitivities discussed from <10^-4 to 10^-6 and associations between MRD negativity and improved outcomes in multiple studies and trials (e.g., FLAIR, MASTER, IFM/Avet‑Loiseau).

The background also notes guideline positions: MRD assessment is an essential component in certain diseases (ALL, MM, CLL) with recommended sensitivity thresholds (NCCN recommends validated MRD assays with 10^-4 sensitivity or better and NGS can reach 10^-6), while MRD role and preferred modalities vary by disease (PCR and flow often preferred in AML; NGS/NGF emphasized in MM and emerging in other settings).

Citation	Key finding
Soderquist et al. (2024)	98% of test outcomes provided helpful clinical data; 89% led to or clarified diagnosis; 19% detected potential therapeutic targets using broad myeloid NGS panels.
FLAIR trial (Munir et al., 2024)	MRD-guided ibrutinib–venetoclax outperformed FCR: PFS 97.2% vs 76.8% at 3 years and OS 98.0% vs 93.0% at 3 years.
MASTER trial (Costa et al., 2023)	MRD-negative (<10^-5) achieved in 81% of evaluable participants; MRD-adapted strategy (MRD‑SURE) led many to discontinue therapy; outcomes varied by high‑risk cytogenetics.
clonoSEQ FDA clearances	FDA reviewed/cleared clonoSEQ for MRD detection/monitoring in B-ALL and MM (2018) and CLL (2020); retrospective and trial data showed undetectable MRD associated with longer event‑free survival.
Wood et al. (2018)	High‑throughput sequencing identified more MRD‑positive pediatric B‑ALL patients than flow cytometry; HTS had higher sensitivity, lower false‑negative rate, and those HTS‑positive/FC‑negative had worse outcomes.
IFM/Avet‑Loiseau et al. (2015)	NGS MRD results predicted PFS in multiple myeloma; NGS detected MRD in patients negative by flow cytometry and associated with different PFS rates (sensitivity to 10^-6 reported).

Definitions

Comprehensive Genomic Profiling (CGP): A type of Next-Generation Sequencing (NGS) test able to detect all classes of genomic alterations, including cancer biomarkers, from a single sample.

Measurable Residual Disease (MRD) — definition 1: A term for a very small number of cancer cells or genetic material detectable during or after treatment that are not seen with routine techniques; used in blood cancers for prognosis and treatment planning.

Measurable Residual Disease (MRD) — definition 2: Presence of residual cancer cells detectable by sensitive assays (flow cytometry, PCR, NGS) during or after treatment and used as a prognostic marker.

Next Generation Sequencing (NGS): Sequencing techniques that can quickly analyze multiple sections of DNA simultaneously, enabling multigene panels, MRD assays, and CGP.

Revision History

07/01/2025material_changeLatest

Material change — Supporting Information Archived previous policy version (LABORATORY 033.4); Applicable CPT codes updated to reflect quarterly edits with addition of CPT codes 0560U and 0561U. (is_material=true)

2025codes_listed

Policy lists applicable CPT/HCPCS and proprietary codes including newly added 0560U: Oncology (MRD) baseline personalized variant panel assessment and 0561U: Oncology (MRD) subsequent assessment for MRD comparison.